SPY312.18+4.10 1.33%
DIA263.17+5.32 2.06%
IXIC9,682.91+74.54 0.78%

Merck Reports KEYTRUDA Superior To Brentuximab Vedotin In Patients With Classical Hodgkin Lymphoma In Head-To-Head Phase 3 Trial

Benzinga · 05/13/2020 21:05